Christophe Le Tourneau

22.6k total citations · 5 hit papers
335 papers, 8.7k citations indexed

About

Christophe Le Tourneau is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Otorhinolaryngology. According to data from OpenAlex, Christophe Le Tourneau has authored 335 papers receiving a total of 8.7k indexed citations (citations by other indexed papers that have themselves been cited), including 189 papers in Oncology, 114 papers in Pulmonary and Respiratory Medicine and 78 papers in Otorhinolaryngology. Recurrent topics in Christophe Le Tourneau's work include Head and Neck Cancer Studies (78 papers), Cancer Immunotherapy and Biomarkers (75 papers) and Lung Cancer Treatments and Mutations (70 papers). Christophe Le Tourneau is often cited by papers focused on Head and Neck Cancer Studies (78 papers), Cancer Immunotherapy and Biomarkers (75 papers) and Lung Cancer Treatments and Mutations (70 papers). Christophe Le Tourneau collaborates with scholars based in France, United States and United Kingdom. Christophe Le Tourneau's co-authors include Lillian L. Siu, Édith Borcoman, Sandrine Faivre, J. Jack Lee, Éric Raymond, Xavier Paolettí, Sanatan Saraf, Vincent Servois, Emilie M.J. van Brummelen and Caroline Even and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Christophe Le Tourneau

313 papers receiving 8.6k citations

Hit Papers

Dose Escalation Methods in Phase I Cancer Clinical Trials 2009 2026 2014 2020 2009 2017 2017 2019 2017 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Dose Escalation Methods in Phase I Cancer Clinical Trials
    2009 568 citations Christophe Le Tourneau, Lillian L. Siu et al. profile →
  2. Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma
    2017 449 citations Esma Saâda-Bouzid, Caroline Even et al. Annals of Oncology profile →
  3. Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1–Positive Cervical Cancer: Results From the Phase Ib KEYNOTE-028 Trial
    2017 386 citations Christophe Le Tourneau, Bert H. O’Neil et al. Journal of Clinical Oncology profile →
  4. Novel patterns of response under immunotherapy
    2019 354 citations Édith Borcoman, Christophe Le Tourneau et al. Annals of Oncology profile →
  5. Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1–Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study
    2017 300 citations Caroline Even, Christophe Le Tourneau et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Christophe Le Tourneau France 46 4.9k 2.3k 2.1k 1.6k 1.3k 335 8.7k
Aaron R. Hansen Canada 39 4.2k 0.9× 2.5k 1.1× 1.8k 0.8× 1.5k 0.9× 2.0k 1.5× 328 7.8k
B. Nebiyou Bekele United States 56 3.8k 0.8× 3.3k 1.5× 3.9k 1.8× 1.4k 0.9× 729 0.5× 137 10.3k
Edward S. Kim United States 52 5.2k 1.1× 5.3k 2.3× 2.9k 1.4× 1.9k 1.2× 691 0.5× 216 9.8k
Alberto Ocaña Spain 51 7.3k 1.5× 2.5k 1.1× 3.8k 1.8× 2.5k 1.5× 950 0.7× 302 12.3k
Sheila E. Taube United States 21 4.5k 0.9× 1.8k 0.8× 3.2k 1.5× 3.5k 2.1× 882 0.7× 38 9.0k
Eric X. Chen Canada 42 2.5k 0.5× 1.6k 0.7× 1.8k 0.9× 878 0.5× 1.6k 1.2× 162 5.7k
Joseph P. Eder United States 47 8.2k 1.7× 3.2k 1.4× 3.4k 1.6× 1.6k 1.0× 1.6k 1.2× 178 12.2k
Zhengjia Chen United States 51 3.1k 0.6× 2.5k 1.1× 2.4k 1.1× 989 0.6× 1.2k 0.9× 267 8.3k
Jonathan D. Cheng United States 43 8.8k 1.8× 3.3k 1.5× 2.3k 1.1× 2.2k 1.3× 2.3k 1.7× 113 12.0k
Jean‐Pierre Delord France 43 5.5k 1.1× 2.0k 0.9× 2.2k 1.1× 1.1k 0.7× 1.1k 0.8× 260 8.4k

Countries citing papers authored by Christophe Le Tourneau

Since Specialization
Citations

This map shows the geographic impact of Christophe Le Tourneau's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christophe Le Tourneau with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christophe Le Tourneau more than expected).

Fields of papers citing papers by Christophe Le Tourneau

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christophe Le Tourneau. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christophe Le Tourneau. The network helps show where Christophe Le Tourneau may publish in the future.

Co-authorship network of co-authors of Christophe Le Tourneau

This figure shows the co-authorship network connecting the top 25 collaborators of Christophe Le Tourneau. A scholar is included among the top collaborators of Christophe Le Tourneau based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christophe Le Tourneau. Christophe Le Tourneau is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Maio, Michele, Víctor Moreno, Juan Martín-Liberal, et al.. (2025). First-in-human phase 1 study of the ICOS agonist feladilimab on patients with advanced solid tumors. Journal for ImmunoTherapy of Cancer. 13(8). e011475–e011475. 1 indexed citations
2.
Kieffer, Yann, Arianna Mencattini, Rana Mhaidly, et al.. (2025). An Extracellular Matrix–Producing Subset of Cancer-Associated Fibroblasts Drives Chemoresistance in Breast Cancer via SRC Activation and G0S2 Upregulation. Cancer Research. 86(4). 1054–1072.
3.
Blin, Olivier, Arnaud Bayle, Christophe Le Tourneau, et al.. (2023). Comment faire entrer la médecine de précision dans la décision thérapeutique de routine au lit du malade ?. Therapies. 79(1). 1–11.
4.
Tourneau, Christophe Le, Massimo Ghiani, M.C. Cau, et al.. (2023). First‐line cetuximab + platinum‐based therapy for recurrent/metastatic head and neck squamous cell carcinoma: A real‐world observational study—ENCORE. Cancer Reports. 6(5). e1804–e1804. 4 indexed citations
5.
Edsjö, Anders, Birgit Geoerger, Frédérique Nowak, et al.. (2023). Precision cancer medicine: Concepts, current practice, and future developments. Journal of Internal Medicine. 294(4). 455–481. 31 indexed citations
6.
Tourneau, Christophe Le, Frédéric Rolland, Olivier Capitain, et al.. (2023). Immunogenicity and clinical activity of tipapkinogen sovacivec (TG4001), an HPV-16 cancer vaccine: A randomized phase 2 study in advanced anogenital cancers.. Journal of Clinical Oncology. 41(16_suppl). 2630–2630.
7.
Chouaïd, C., et al.. (2023). Organizational Impact of Immunotherapies in Advanced Cancers in France. JCO Global Oncology. 9(9). e2300026–e2300026.
8.
9.
Fayette, Jérôme, Caroline Even, Laurence Digue, et al.. (2023). NISCAHN: a phase II trial of nivolumab in patients with salivary gland carcinoma (Unicancer ORL-08). SHILAP Revista de lepidopterología. 2(1). e000065–e000065. 6 indexed citations
10.
Jeannot, Emmanuelle, Aurélien Latouche, Claire Bonneau, et al.. (2022). 2022-RA-205-ESGO Circulating HPV DNA in cervical cancer: a marker for early detection of relapse. International Journal of Gynecological Cancer. 32. A404–A404. 1 indexed citations
11.
Tourneau, Christophe Le, Allan Hackshaw, Jean‐Yves Blay, et al.. (2022). An Approach to Solving the Complex Clinicogenomic Data Landscape in Precision Oncology: Learnings From the Design of WAYFIND-R, a Global Precision Oncology Registry. JCO Precision Oncology. 6(6). e2200019–e2200019. 8 indexed citations
12.
Saleh, Khalil, Anne Aupérin, Nicolas Martin, et al.. (2021). Efficacy and safety of immune checkpoint inhibitors in elderly patients (≥70 years) with squamous cell carcinoma of the head and neck. European Journal of Cancer. 157. 190–197. 10 indexed citations
13.
Hoffmann, Caroline, Valentin Calugaru, Édith Borcoman, et al.. (2021). Phase I dose-escalation study of NBTXR3 activated by intensity-modulated radiation therapy in elderly patients with locally advanced squamous cell carcinoma of the oral cavity or oropharynx. European Journal of Cancer. 146. 135–144. 45 indexed citations
14.
Tourneau, Christophe Le, Yungan Tao, Carlos Gomez‐Roca, et al.. (2020). Phase I Trial of Debio 1143, an Antagonist of Inhibitor of Apoptosis Proteins, Combined with Cisplatin Chemoradiotherapy in Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck. Clinical Cancer Research. 26(24). 6429–6436. 22 indexed citations
15.
Emancipator, Kenneth, Lingkang Huang, Deepti Aurora-Garg, et al.. (2020). Comparing programmed death ligand 1 scores for predicting pembrolizumab efficacy in head and neck cancer. Modern Pathology. 34(3). 532–541. 71 indexed citations
16.
Hoff, Daniel D. Von, Drew Rasco, Elisabeth I. Heath, et al.. (2018). Phase I Study of CC-486 Alone and in Combination with Carboplatin or nab-Paclitaxel in Patients with Relapsed or Refractory Solid Tumors. Clinical Cancer Research. 24(17). 4072–4080. 27 indexed citations
17.
Pierron, Gaëlle, Paul Fréneaux, Sophie Huybrechts, et al.. (2017). NUT carcinoma in children and adults: A multicenter retrospective study. Pediatric Blood & Cancer. 64(12). 64 indexed citations
18.
Birzele, Fabian, Edgar Voß, Adam Nopora, et al.. (2015). CD44 Isoform Status Predicts Response to Treatment with Anti-CD44 Antibody in Cancer Patients. Clinical Cancer Research. 21(12). 2753–2762. 45 indexed citations
19.
Calugaru, Valentin, Nicolas Magné, J. Hérault, et al.. (2015). SynthèseNanoparticules et radiothérapieNanoparticles and radiation therapy. Bulletin du Cancer. 102(1). 11 indexed citations
20.
Malouf, Gabriel G., Chantal Dreyer, Nathalie Guedj, et al.. (2009). Facteurs pronostiques des cholangiocarcinomes : apport des données récentes de biologie moléculaire. Bulletin du Cancer. 96(4). 405–415. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Aaron R. Hansen Breakdown of academic impact, for papers by B. Nebiyou Bekele Breakdown of academic impact, for papers by Edward S. Kim Breakdown of academic impact, for papers by Alberto Ocaña Breakdown of academic impact, for papers by Sheila E. Taube Breakdown of academic impact, for papers by Eric X. Chen Breakdown of academic impact, for papers by Joseph P. Eder Breakdown of academic impact, for papers by Zhengjia Chen Breakdown of academic impact, for papers by Jonathan D. Cheng Breakdown of academic impact, for papers by Jean‐Pierre Delord
Rankless by CCL
2026